Adagio Medical Holdings

Adagio Medical Holdings, Inc. is a medical device company, which engages in the development ablation technologies for the treatment of cardiac arrhythmias. The company is headquartered in Laguna Hills, California and currently employs 41 full-time employees. The company went IPO on 2021-02-26. The firm is focused on developing and commercializing products for the treatment of cardiac arrhythmias with catheter-based ultra-low temperature ablation (ULTA) technology, formerly known as ultra-low temperature cryoablation (ULTC) technology. Its initial focus is on the treatment of ventricular tachycardia (VT), which is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart’s lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, it can be fatal. Its ULTA products are purpose-built to treat patients with VT and are designed to address the unique anatomy of the ventricle and the specific needs of the VT patient. Its catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle through a stable, endocardial or inside the heart approach with no required irrigation.